Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $30.2727.

BCAX has been the subject of several recent research reports. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. HC Wainwright increased their target price on Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Morgan Stanley increased their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Bank of America assumed coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 target price for the company.

Insider Activity

In related news, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $23.01, for a total transaction of $287,625.00. Following the completion of the sale, the chief operating officer directly owned 196,141 shares of the company’s stock, valued at approximately $4,513,204.41. This trade represents a 5.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $23.61, for a total transaction of $354,150.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $8,550,408.72. The trade was a 3.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 174,310 shares of company stock valued at $3,459,283 in the last 90 days. Company insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in BCAX. Siren L.L.C. grew its stake in Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after purchasing an additional 586,001 shares in the last quarter. Vestal Point Capital LP grew its stake in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after purchasing an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics during the 4th quarter valued at approximately $44,484,000. Finally, Vanguard Group Inc. grew its stake in Bicara Therapeutics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after purchasing an additional 195,667 shares in the last quarter.

Bicara Therapeutics Stock Down 1.6%

Bicara Therapeutics stock opened at $20.65 on Friday. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $24.25. The firm has a fifty day moving average of $20.98 and a 200-day moving average of $18.17. The firm has a market capitalization of $1.36 billion, a P/E ratio of -7.43 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, research analysts expect that Bicara Therapeutics will post -3.37 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.